At Moderna, we are committed to rules, policies and processes of solid corporate governance in order to uphold the interests of our diverse set of stakeholders and establish clear expectations with respect to how we conduct our business. Below is a list of Moderna’s board members. Details on our board committees and committee composition can be found here.
- Noubar Afeyan, Ph.D., Co-founder and Chairman, Moderna; CEO, Flagship Pioneering
- Stéphane Bancel, Chief Executive Officer, Moderna
- Stephen Berenson, Executive Partner, Flagship Pioneering
- Peter Barton Hutt, Senior Counsel, Covington & Burling
- Robert Langer, Sc.D., Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT
- John Mendlein, Ph.D., Executive Chairman and CEO of aTyr Pharma
- Elizabeth Nabel, M.D., President, Brigham Health
- Israel Ruiz, Audit Committee Chair, Moderna; Executive Vice President and Treasurer, Massachusetts Institute of Technology
- Moncef Slaoui, Ph.D., Former Chairman of Global Vaccines, GlaxoSmithKline PLC (GSK)
- Henri A. Termeer, Retired Chairman, President, and CEO of Genzyme - In Memoriam
Noubar Afeyan, Ph.D.
Co-founder and Chairman, Moderna; CEO, Flagship Pioneering
Noubar Afeyan, Ph.D., is co-founder and chairman of Moderna, and CEO of Flagship Pioneering, a leading early stage venture capital firm. He also leads the firm’s VentureLabs unit that invents and launches transformative startups. He is a senior lecturer at MIT’s Sloan School of Management where he has taught courses on technology entrepreneurship, innovation, and leadership since 2000. Dr. Afeyan has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. He lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation, and venture capital to biological engineering, drug discovery, medical technologies, and renewable energy. During his 24-year career as inventor, entrepreneur, CEO and venture capitalist, Dr. Afeyan has co-founded and helped build 24 successful life science and technology startups.
Currently Dr. Afeyan serves on a number of public and private company boards in addition to Moderna, and he is a member of several advisory boards including the Yale Climate & Energy Initiative and the SKOLKOVO School of Management in Moscow. He is also a member of the board of overseers of the Boston Symphony Orchestra. Previously, he was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100 million in annual sales within six years from its first sales, and he was a member of the founding team, director, and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb).
Chief Executive Officer, Moderna
Stéphane Bancel joined Moderna joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised nearly $2 billion between equity financing and upfront from licensing collaborations.
He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMérieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion.
Prior to his time at bioMérieux, Mr. Bancel was the managing director of Eli Lilly Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.
He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.
Mr. Bancel was named Ernst & Young 2017 New England Entrepreneur of the Year. He was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. In 2009, he was elected a Young Global Leader by the World Economic Forum, and elected best CEO for investor relations in France.
Mr. Bancel serves as a supervisory director of Qiagen N.V. He also serves on the Board of Trustees for the Museum of Science, Boston.
Executive Partner, Flagship Pioneering
Stephen Berenson is executive partner at Flagship Pioneering and is a member of the firm’s Investment and Management Committees. He focuses on capital formation at the fund and portfolio company levels and helps the firm’s management teams grow and realize value. Stephen also drives strategic and operational improvements across the firm and its portfolio of companies, and helps deepen relationships with critical, external partners.
Stephen joined Flagship after a 33-year career as an investment banker at J.P. Morgan. During that time, he worked across all major geographies, product areas and industry groups, and he was a key player in building the bank’s M&A, equities and technology investment banking businesses. During his last twelve years at J.P. Morgan, Stephen was vice chairman of investment banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. During Stephen’s leadership of the Board Initiative, more than 1,000 independent directors of public companies attended at least one of J.P. Morgan’s board events to discuss, debate and share best practices on the key issues they faced in the fulfillment of their duties.
Stephen also made important contributions to J.P. Morgan’s culture through his deep support of recruiting, training and development, and mentoring, and he helped to build and maintain a robust control environment through his participation on the firm’s Equity Underwriting and Reputational Risk Committees.
Stephen graduated from MIT in 1982 with an S.B. in mathematics. He is a member of the board of trustees of the Mahaiwe Performing Arts Center in Great Barrington, Massachusetts.
Peter Barton Hutt
Senior Counsel, Covington & Burling
Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling, specializing in food and drug law. He began his law practice with the firm in 1960 and, except for his four years in the government, has continued at the firm ever since. From 1971 to 1975 he was chief counsel for the Food and Drug Administration (FDA).
Since 1994, he has taught a full course on food and drug law during winter term at Harvard Law School (“Winter Term: Food and Drug Law,” http://blogs.law.harvard.edu/admissions/2011/01/20) and taught the same course at Stanford Law School during spring term in 1998. He is the co-author of Food and Drug Law: Cases and Materials, and has published more than 175 book chapters and articles on food and drug law and health policy. He has represented the national trade associations for the food, prescription drug, nonprescription drug, dietary supplement, and cosmetic industries. While at the FDA, he drafted the legislation that became the Medical Device Amendments of 1976, and beginning in 1962 he has participated in the drafting of most of the major legislation amending the Federal Food, Drug, and Cosmetic Act. He has testified before the House and Senate more than 100 times either as counsel accompanying a witness or as a witness. Mr. Hutt has been a member of the Institute of Medicine (IOM) of the National Academy of Sciences (NAS) since it was formed in 1971. He has served on the IOM Executive Committee and other NAS and IOM committees. He recently served as a member of the Working Group on Innovation in Drug Development and Evaluation for President Obama’s Council of Advisors on Science and Technology (PCAST); on the Science Review Subcommittee of the FDA Science Board to review the FDA science needs in order to perform its regulatory mission; the Panel on the Administrative Restructuring of the National Institutes of Health; and the Working Group to Review Regulatory Activities Within the Division of AIDS of the National Institute of Allergy and Infectious Diseases. He is a member of the board of directors of the AERAS Global TB Vaccine Foundation, the Foundation for Biomedical Research, the California Healthcare Institute, the Institute of Health Policy Analysis, and the Keck Graduate Institute of Applied Life Sciences, one of the Claremont Colleges. He serves on a wide variety of other academic and scientific advisory boards, on the boards of directors of venture capital startup companies, and on advisory boards of venture capital firms.
He was named by The Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people. In April 2005, Mr. Hutt was presented the Distinguished Alumni Award by FDA. In May 2005, he was given the Lifetime Achievement Award for research advocacy by the Foundation for Biomedical Research.
Robert Langer, Sc.D.
Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT
Robert S. Langer, Sc.D., is the David H. Koch Institute Professor at MIT (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written more than 1,180 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.
He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
Dr. Langer has received over 250 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineer; the 2008 Millennium Prize, the world’s largest technology prize; and the 2012 Priestley Medal, the highest award of the American Chemical Society. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention, for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.
John Mendlein, Ph.D.
Executive Chairman & CEO, aTyr Pharma
John Mendlein, Ph.D., is executive chairman and CEO of aTyr Pharma (novel protein therapeutics) and vice chairman of Fate Therapeutics (drugs for stem cells), two privately held biotech companies in San Diego. Prior to his involvement in these enterprises, he served as CEO of Adnexus Therapeutics (a pioneer of a new class of protein therapeutics) which was purchased by Bristol-Myers Squibb Company (BMY) for $505 million.
Previously, Dr. Mendlein served as chairman and CEO at Affinium Pharmaceuticals, Inc., and served in a variety of roles, including board member, general counsel, and chief knowledge officer, at Aurora Biosciences (acquired by Vertex Pharmaceuticals, VRTX), a biotechnology company focused on discovering drugs for ion channels, including CFTR, which led to the discovery of a breakthrough medicine, Kaledyco, approved in 2012 for cystic fibrosis.
Dr. Mendlein has worked at Smith Kline & French, now GlaxoSmithKline (GSK), as a scientist in the Department of Molecular Biology and Protein Expression; at Cooley LLP, a law firm, as an attorney in its life sciences and technology litigation practice groups; and served as a board member of Monogram Biosciences (MGRM, acquired by Lab Corp, LH). He is currently an advisory board member of Genesys Capital, a venture capital firm in Canada; a founder and board member of Homes for Sudan, a not for profit in Boston; and a scientific advisory board member for Ocean Discovery Institute, a not for profit in San Diego.
Dr. Mendlein is the author or inventor of over 70 publications and patents. He has won various awards for his work in biotechnology and science, as well as write-ups of various business endeavors in the Wall Street Journal, Financial Times, and Newsweek. Dr. Mendlein earned his Ph.D. in physiology and biophysics from the University of California, Los Angeles; a JD from the University of California Hastings School of Law; and a B.S. in biology from the University of Miami.
Elizabeth Nabel, M.D.
President, Brigham Health
Elizabeth (Betsy) Nabel, M.D., has served as president of Harvard-affiliated Brigham Health--an academic health care system which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization--since 2010. A cardiologist and distinguished biomedical researcher, Nabel is Professor of Medicine at Harvard Medical School.
Nabel brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader, and wellness advocate. At Brigham Health, Nabel is leading development of a new model of academic medicine devoted to maintaining and restoring health through leadership in scientific discovery, education, and compassionate care. Initiatives include a new translational research and clinical facility, leading-edge care redesign, and a $1.5 billion campaign to advance life-giving breakthroughs.
Building on her lifelong commitment to improving health through science, in 2015 Nabel was appointed chief health and medical advisor to the National Football League. In this newly created advisory role, Nabel provides strategic input to the NFL’s medical, health and scientific efforts; participates as an ex-officio member on each of the NFL’s medical advisory committees; and identifies areas for the NFL to enhance player safety, care and treatment.
Nabel has a long record of advocacy for health and broadening access to care. As director of the National Heart, Lung, and Blood Institute from 2005-2009, Nabel leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research. One of her signature advocacy efforts was the Red Dress Heart Truth campaign, which raises heart awareness in women through unprecedented industry partnerships.
An accomplished physician-scientist, Nabel’s work on the molecular genetics of cardiovascular diseases has produced17 patents and more than 250 scientific publications. Nabel’s scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques, delineated that the pathophysiology of atherosclerosis and clarified the processes of cell division and growth of vascular smooth muscle cells in blood vessels. Her studies on Hutchinson-Gilford Progeria Syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke.
Nabel has been named one of the nation’s top leaders in medicine by Modern Healthcare and Becker’s Hospital Review, and one of Boston’s 50 most powerful people by Boston Magazine. Her honors include the Distinguished Bostonian Award from the Greater Boston Chamber of Commerce, the Kober Medal from the Association of American Physicians, the Champion in Health Care award from the Boston Business Journal, the Willem Einthoven Award from Leiden University in the Netherlands, the Amgen-Scientific Achievement Award, two Distinguished Achievement Awards and the Eugene Braunwald Academic Mentorship Award from the American Heart Association, and six honorary doctorates.
Her colleagues have elected her to the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science. Nabel serves on the boards of Medtronic, Moderna Therapeutics, the Broad Institute, Ariadne Labs, the Boys & Girls Club of Boston, and the Medical Advisory Board of the Howard Hughes Medical Institute, and previously served on the editorial boards for the New England Journal of Medicine, Science, and Science Translational Medicine as well as editor-in-chief of Scientific American Medicine.
A native of St. Paul, Minnesota, Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital. She and her husband Gary, who is the chief scientific officer for Sanofi, have three children, all of whom are pursuing careers in medicine.
Audit Committee Chair, Moderna; Executive Vice President and Treasurer, Massachusetts Institute of Technology
Israel Ruiz, Executive Vice President and Treasurer of the Massachusetts Institute of Technology (MIT), serves as Audit Committee Chair on Moderna’s Board of Directors.
As MIT’s Chief Financial Officer, a Trustee of the MIT Corporation and a member of its Executive Committee, Mr. Ruiz is the chief steward of over $17 billion of financial assets, $3.4 billion in operating revenues and is responsible for administering MIT’s $5 billion capital plan through 2030.
At MIT, Mr. Ruiz is responsible for financial and debt strategy development, budget and capital planning, and the integrity of financial information. His other areas of responsibility include human resources, information systems, campus facilities, security and safety, compliance, government relations, international support, sustainability, and medical.
Prior to becoming Executive Vice President and Treasurer in 2011, Mr. Ruiz held several roles of increasing responsibility at MIT, most recently serving as Vice President of Finance. Mr. Ruiz previously held management and engineering roles at Hewlett-Packard and Nissan Automotive.
Mr. Ruiz was instrumental in leading the re-zoning efforts of Kendall Square in Cambridge, Mass. in 2013 to enable mixed-use development and accelerate the process of moving ideas from lab to market. He continues to actively co-lead the development of the process through its complex execution phase, expected to last beyond 2020.
Mr. Ruiz serves on the Board of Directors of edX (an MIT and Harvard on-line learning initiative), MIT Endicott House, MIT Technology Review and MIT’s The Engine. He serves as Audit Committee Chair on the Board of Directors of Fortive (NYSE: FTV), a 2016 spin-out of Danaher (NYSE: DHR). He is also a director of the Governing Board of the Eliot Innovation School and is very active in the Boston Public Schools.
Mr. Ruiz holds a master’s degree from the MIT Sloan School of Management and a six-year degree in industrial and mechanical engineering from the Polytechnic University of Catalonia, in his native Barcelona.
Moncef Slaoui, Ph.D.
Former Chairman of Global Vaccines, GlaxoSmithKline PLC (GSK)
Moncef M. Slaoui, Ph.D., previously served as the Chairman of Global Vaccines at GlaxoSmithKline PLC (GSK). His previous roles at GSK also included Chairman of Global Research and Development and Vaccines, Chairman of Research and Development, and Senior Vice President of Worldwide Business Development and External Alliances. Dr. Slaoui was Chairman of GSK’s Pipeline Investment Board (PIB) between 2006 and 2015 and served as a Director of GSK from 2006 to 2017. He currently serves as Chairman of the Board of Galvani, a bioelectronics-dedicated biotech co-owned by GSK and Verily, an Alphabet company. Dr. Slaoui previously was a member of the Advisory Board of the Agency for Science, Technology and Research, or A*STAR, in Singapore, and a member of the National Institutes of Health’s (NIH) Advisory Committee to the Director. He currently serves as a member of the Advisory Board to the Qatar Foundation.
Dr. Slaoui was a Professor of Immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations. Dr. Slaoui earned a Ph.D. in Molecular Biology and Immunology from the University Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
Henri A. Termeer - In Memoriam
Retired Chairman, President, and CEO of Genzyme
Henri A. Termeer served as chairman, president, and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company’s founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion.
Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer was active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care.
Mr. Termeer was a board member of Massachusetts Institute of Technology Corporation and served on its executive committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School, and on the board of the Biotechnology Industry Organization (BIO). He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and was a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer was also chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He was elected a fellow of the American Academy of Arts and Sciences in 1999.
Mr. Termeer was chairman of the Federal Reserve Bank of Boston’s board of directors from 2010-2011 and served on the board of directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an MBA from the Darden School at the University of Virginia. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the health care and entrepreneurial fields.